AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: 24737778
Drug: Tivantinib 360
RxNorm normalized name: Tivantinib
DrugBank: Tivantinib (DB12200)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tivantinib 360 mg b.i.d. with gemcitabine
Trial: 24738629
Drug: Idarubicin-loaded beads
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Idarubicin-loaded beads (2 mL drug-eluting beads; DC Bead 300-500 μm) at 5 mg
Trial: 24738629
Drug: Idarubicin-loaded beads
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Idarubicin-loaded beads (2 mL drug-eluting beads; DC Bead 300-500 μm) at 10 mg
Trial: 24738629
Drug: Idarubicin-loaded beads
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Idarubicin-loaded beads (2 mL drug-eluting beads; DC Bead 300-500 μm) at 15 mg
Trial: 24738629
Drug: Idarubicin-loaded beads
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Idarubicin-loaded beads (2 mL drug-eluting beads; DC Bead 300-500 μm)
Trial: 24739978
Drug: Nonadjuvanted cell
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Nonadjuvanted cell culture-derived whole-virus H5N1 vaccine; two priming immunizations with clade 1 A/Vietnam H5N1 vaccine, booster with clade 2.1 A/Indonesia H5N1 vaccine 12 to 24 months later.
Trial: 24739978
Drug: Safety and
RxNorm normalized name: HYDROCORTISONE ACETATE 10 mg in 1 g TOPICAL CREAM [American Safety and First Aid]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Safety and tolerability of the vaccine.
Trial: 24741582
Drug: Rituximab monotherapy
RxNorm normalized name: Rituximab
DrugBank: Rituximab (DB00073)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Rituximab monotherapy (4 weekly doses)
Trial: 24741582
Drug: Rituximab monotherapy
RxNorm normalized name: Rituximab
DrugBank: Rituximab (DB00073)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Rituximab monotherapy followed by CHOP-21 (16 out of 25 patients)
Trial: 24742768
Drug: Tadalafil 40
RxNorm normalized name: tadalafil 40 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tadalafil 40 mg/d
Trial: 24743000
Drug: rAvPAL-PEG (0.100
FDA approved: no
EMA approved: no
PMDA approved: no
Description: rAvPAL-PEG (0.100 mg/kg)
Trial: 24743391
Drug: Long-term parenteral
RxNorm normalized name: benzethonium
DrugBank: Benzethonium (DB11125)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Long-term parenteral nutrition (PN)
Trial: 24746841
Drug: MABp1 (anti-interleukin-1α
FDA approved: no
EMA approved: no
PMDA approved: no
Description: MABp1 (anti-interleukin-1α monoclonal antibody) at 3.75 mg/kg every 2 weeks
Trial: 24746841
Drug: MABp1 (anti-interleukin-1α
FDA approved: no
EMA approved: no
PMDA approved: no
Description: MABp1 (anti-interleukin-1α monoclonal antibody)
Trial: 24747207
Drug: Demethylation treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Demethylation treatment with 5-aza-2'-deoxycytide
Trial: 24747949
Drug: Rituximab (375
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Rituximab (375 mg/m² × 4 infusions) combined with three cycles of dexamethasone (28 mg/m², max. 40 mg) for 4 days at 2-week intervals
Trial: 24748824
Drug: New disposable
FDA approved: no
EMA approved: no
PMDA approved: no
Description: New disposable injection pen (GoQuick(®), Pfizer, Inc.)
Trial: 24751453
Drug: adalimumab 40
RxNorm normalized name: ADALIMUMAB 40MG/0.8ML INJ,PEN,KIT
FDA approved: no
EMA approved: no
PMDA approved: no
Description: adalimumab 40 mg weekly for 45 weeks
Trial: 24752449
Drug: LY2523355 (litronesib)
RxNorm normalized name: Litronesib
DrugBank: Litronesib (DB11861)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: LY2523355 (litronesib) at 2 mg/m²/day
Trial: 24752449
Drug: LY2523355 (litronesib)
RxNorm normalized name: Litronesib
DrugBank: Litronesib (DB11861)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: LY2523355 (litronesib) at 4 mg/m²/day
Trial: 24752449
Drug: LY2523355 (litronesib)
RxNorm normalized name: Litronesib
DrugBank: Litronesib (DB11861)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: LY2523355 (litronesib) at 5 mg/m²/day
Trial: 24753695
Drug: Oral cholera
RxNorm normalized name: VIBRIO CHOLERAE
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral cholera vaccine (OCV) - 2 doses with a 2-week interval
Trial: 24754273
Drug: IV abatacept
RxNorm normalized name: Abatacept
DrugBank: Abatacept (DB01281)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: IV abatacept (10 mg/kg weight-tiered dosing) with MTX (up to 8 mg/week)
Trial: 24754273
Drug: IV abatacept
RxNorm normalized name: Abatacept
DrugBank: Abatacept (DB01281)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: IV abatacept (10 mg/kg weight-tiered dosing) monotherapy
Trial: 24754273
Drug: IV abatacept
RxNorm normalized name: Abatacept
DrugBank: Abatacept (DB01281)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: IV abatacept (10 mg/kg weight-tiered dosing) with and without background MTX
Trial: 24755296
Drug: Capecitabine 750
RxNorm normalized name: Capecitabine
DrugBank: Capecitabine (DB01101)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Capecitabine 750 mg/m2 twice a day during days 1-7, oxaliplatin 85 mg/m2 and bevacizumab 5 mg/kg on day 1, repeated every 14 days
Trial: 24755296
Drug: Capecitabine, oxaliplatin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Capecitabine, oxaliplatin and bevacizumab combination
Trial: 24755302
Drug: Left ventricular
RxNorm normalized name: DRESSING,VENTRICULAR ASSIST DEVICE
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Left ventricular contrast injection with rotational C-arm CT (LV-RCT)
Trial: 24755302
Drug: Aortic contrast
RxNorm normalized name: Contrased
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Aortic contrast injection with rotational C-arm CT (Ao-RCT)
Trial: 24758527
Drug: FOLFIRI® +
FDA approved: no
EMA approved: no
PMDA approved: no
Description: FOLFIRI® + bevacizumab (5 mg/kg bevacizumab, 180 mg/m2 irinotecan, 400 mg/m2 bolus FU, 400 mg/m2 leucovorin, followed by 46-hour FU infusions (2400 mg/m2))
Trial: 24758722
Drug: Step-down treatment
RxNorm normalized name: Kool-Down
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Step-down treatment program (including short-term day hospital treatment followed by combined group and individual psychotherapy)
Trial: 24758722
Drug: Both treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Both treatment groups (Outpatient and Step-down)
Trial: 24759933
Drug: Chewable tablets
RxNorm normalized name: Pepcix Chewable Tablets
DrugBank: Bismuth subsalicylate (DB01294)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Chewable tablets
Trial: 24760402
Drug: Dexmecamylamine 8
RxNorm normalized name: Dexmecamylamine
DrugBank: Dexmecamylamine (DB11807)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dexmecamylamine 8 mg (normal renal function and mild renal impairment)
Trial: 24760402
Drug: TC-5412 2
RxNorm normalized name: TC-6987
DrugBank: TC-6987 (DB14854)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: TC-5412 2 mg (moderate renal impairment and ESRD)
Trial: 24760402
Drug: Dexmecamylamine (single
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dexmecamylamine (single oral dose)
Trial: 24761968
Drug: Bortezomib and
RxNorm normalized name: Bortezomib
DrugBank: Bortezomib (DB00188)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Bortezomib and rituximab (3 induction cycles of weekly administration)
Trial: 24763770
Drug: Telephone-administered cognitive-behavioral
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Telephone-administered cognitive-behavioral therapy for depression
Trial: 24763965
Drug: Statin therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Statin therapy (n=186)
Trial: 24763965
Drug: No statin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: No statin therapy (n=95)
Trial: 24764034
Drug: Steroid-based therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Steroid-based therapy (40 mg to 50 mg prednisone per day)
Trial: 24764124
Drug: Veliparib (ABT-888)
RxNorm normalized name: ABT-925
DrugBank: Veliparib (DB07232)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Veliparib (ABT-888) 40 mg twice daily on days 1-7 and temozolomide (TMZ) 150 mg/m(2)/day for cycle 1, then 200 mg/m(2)/day for cycle 2 onwards on days 1-5 q28 days.
Trial: 24764124
Drug: Veliparib and
RxNorm normalized name: cytarabine and daunorubicin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Veliparib and TMZ combination treatment.
Trial: 24766766
Drug: Plant stanol
RxNorm normalized name: plant stanol ester
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Plant stanol ester (STAEST) intervention, doses varied from 0.8 to 8.8 g/d, duration from 4 to 52 weeks.
Trial: 24771350
Drug: ASP9521 (30
FDA approved: no
EMA approved: no
PMDA approved: no
Description: ASP9521 (30 mg/day for 12 weeks)
Trial: 24773782
Drug: Anti-HEV IgG
RxNorm normalized name: Anti Bac
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Anti-HEV IgG antibodies
Trial: 24777247
Drug: Repeated infusions
RxNorm normalized name: eicosyl povidone (2 eicosyl branches-repeat)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Repeated infusions of CAR-T cells
Trial: 24777716
Drug: Eculizumab (600
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Eculizumab (600 mg weekly for 4 weeks, 900 mg in week 5, and 900 mg every 2 weeks thereafter)
Trial: 24782620
Drug: Hansenula-derived PEGylated
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Hansenula-derived PEGylated interferon alpha-2a plus ribavirin for 12 weeks (weekly subcutaneous injection of PEG-IFN-alpha-2a plus daily oral ribavirin).
Trial: 24782620
Drug: Extended treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Extended treatment course up to 72 weeks for patients who were PCR-negative at week 48 but had at least one PCR-positive test during therapy.
Trial: 24782620
Drug: 5-day treatment
RxNorm normalized name: 30 day Acne Treatment Kit KIT
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 5-day treatment schedule of PEG-IFN-alpha-2a plus ribavirin.
Trial: 24782620
Drug: Assessment of
RxNorm normalized name: OIL OF CAMPHOR
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Assessment of liver transaminases before and after treatment.
Trial: 24782684
Drug: HMBFA-HIIT (3
FDA approved: no
EMA approved: no
PMDA approved: no
Description: HMBFA-HIIT (3 g per day of HMBFA)
Trial: 24786603
Drug: Sorafenib (200
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sorafenib (200 mg BID) combined with radiation therapy (60 Gy in 2 Gy fractions) and temozolomide (75 mg/m² daily)
Trial: 24786603
Drug: Sorafenib (400
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sorafenib (400 mg BID) combined with radiation therapy and temozolomide
Trial: 24787738
Drug: Intravenous azithromycin
RxNorm normalized name: Azithromycin
DrugBank: Azithromycin (DB00207)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Intravenous azithromycin (500 mg, once daily) for 1 or 2 days followed by oral azithromycin (250 mg once daily) to complete a total of 7 days treatment
Trial: 24789707
Drug: Functional L
RxNorm normalized name: L-377202
DrugBank: L-377202 (DB19022)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Functional L lesion
Trial: 24789707
Drug: Clots categorized
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Clots categorized as L lesion
Trial: 24794216
Drug: High on-aspirin
RxNorm normalized name: high-density polyethylene
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High on-aspirin platelet reactivity (OAR)
Trial: 24794216
Drug: High vs.
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High vs. normal on-treatment platelet reactivity
Trial: 24794806
Drug: SAR103168, a
FDA approved: no
EMA approved: no
PMDA approved: no
Description: SAR103168, a novel multi-targeted kinase inhibitor
Trial: 24794816
Drug: Nicotinamide (2-8
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Nicotinamide (2-8 g oral) for 5 days and 8 weeks, with doses gradually escalated during phases 1 and 2.
Trial: 24794816
Drug: Nicotinamide (3.5-6
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Nicotinamide (3.5-6 g daily) for 8 weeks.
Trial: 24794816
Drug: Nicotinamide (high-dose)
DrugBank: Nicotinamide (DB02701)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Nicotinamide (high-dose)
Trial: 24797180
Drug: Reduced-toxicity conditioning
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Reduced-toxicity conditioning (RTC) regimen of BU 12.8-16 mg/kg, fludarabine 180 mg/m², alemtuzumab 54 mg/m² (BFA) before HLA-matched sibling donor transplantation
Trial: 24797373
Drug: Activities of
RxNorm normalized name: Activated Charcoal
DrugBank: Activated charcoal (DB09278)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Activities of spiritual care providers (discussions about patient's end-of-life wishes, preparation for family conference, total number of activities performed)
Trial: 24798021
Drug: Oral posaconazole
RxNorm normalized name: Posaconazole
DrugBank: Posaconazole (DB01263)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Oral posaconazole with intravenous micafungin bridging (POS-MIC)
Trial: 24798021
Drug: Oral posaconazole
RxNorm normalized name: Posaconazole
DrugBank: Posaconazole (DB01263)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Oral posaconazole (POS)
Trial: 24800949
Drug: Paclitaxel 80
RxNorm normalized name: Paclitaxel
DrugBank: Paclitaxel (DB01229)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Paclitaxel 80 mg/m², Pazopanib 400 mg, Lapatinib 1000 mg
Trial: 24800949
Drug: Paclitaxel 80
RxNorm normalized name: Paclitaxel
DrugBank: Paclitaxel (DB01229)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Paclitaxel 80 mg/m² with Pazopanib 400 mg and Lapatinib 1000 mg
Trial: 24801836
Drug: Intratumoral and
RxNorm normalized name: cytarabine and daunorubicin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intratumoral and intramuscular injections of polyinosinic-polycytidylic acid-polylysine-carboxymethylcellulose (poly-ICLC)
Trial: 24802773
Drug: Eltrombopag (50
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Eltrombopag (50 mg, days 5-32) + Dexamethasone (40 mg by mouth, days 1-4)
Trial: 24807459
Drug: Linifanib (7.5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Linifanib (7.5 mg and 12.5 mg) in combination with carboplatin (AUC = 6 mg/mL/min) and paclitaxel (200 mg/m²)
Trial: 24807459
Drug: Linifanib (12.5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Linifanib (12.5 mg)
Trial: 24807889
Drug: VTX-2337 (0.1-3.9
FDA approved: no
EMA approved: no
PMDA approved: no
Description: VTX-2337 (0.1-3.9 mg/m(2)) administered subcutaneously on days 1, 8, and 15 of each 28-day cycle
Trial: 24808483
Drug: Antenatal corticosteroid
RxNorm normalized name: abiraterone and corticosteroids
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Antenatal corticosteroid treatment
Trial: 24811751
Drug: varenicline (0.25
FDA approved: no
EMA approved: no
PMDA approved: no
Description: varenicline (0.25 mg BID, 0.5 mg BID, 1 mg BID)
Trial: 24811754
Drug: SC serum-free
RxNorm normalized name: Serum, horse
DrugBank: Serum, horse (DB14613)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: SC serum-free interferon β-1a 44 μg or 22 μg 3 times weekly for 12 months
Trial: 24814620
Drug: HPV-16/18 AS04-adjuvanted
FDA approved: no
EMA approved: no
PMDA approved: no
Description: HPV-16/18 AS04-adjuvanted vaccine (Cervarix©)
Trial: 24814743
Drug: Comprehensive, validated
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Comprehensive, validated questionnaire on functional impairments and QoL administered at diagnosis and after one, two, and five years.
Trial: 24816856
Drug: Eliglustat (50
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Eliglustat (50 or 100 mg) self-administered orally twice daily
Trial: 24816908
Drug: Combination of
RxNorm normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination of ganitumab (18 mg/kg) and conatumumab (15 mg/kg)
Trial: 24817603
Drug: Sorafenib (200
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sorafenib (200 mg BiD for 5 days every week) + Bevacizumab (5 mg/kg intravenously every 14 days)
Trial: 24819685
Drug: OPB-31121 at
RxNorm normalized name: AT-III
DrugBank: Antithrombin III human (DB11598)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: OPB-31121 at 300 mg BID
Trial: 24819685
Drug: OPB-31121 at
RxNorm normalized name: AT-III
DrugBank: Antithrombin III human (DB11598)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: OPB-31121 at 350 mg BID
Trial: 24819685
Drug: Pharmacokinetics of
RxNorm normalized name: OIL OF CAMPHOR
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pharmacokinetics of OPB-31121
Trial: 24821883
Drug: Neoadjuvant dose-dense
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Neoadjuvant dose-dense methotrexate, vinblastine, doxorubicin, and cisplatin (ddMVAC) with pegfilgrastim support
Trial: 24823675
Drug: Anaemia (defined
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Anaemia (defined as haemoglobin <12 g/dL for women and <13 g/dL for men)
Trial: 24824628
Drug: Cisplatin 25
RxNorm normalized name: Cisplatin
DrugBank: Cisplatin (DB00515)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Cisplatin 25 mg/m² on days 1-3 and gemcitabine 1,000 mg/m² on days 1 and 8 for up to 8 cycles
Trial: 24824852
Drug: Weekly dose-intensified
RxNorm normalized name: selinexor
DrugBank: Selinexor (DB11942)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Weekly dose-intensified cisplatin (30 mg/m²), epirubicin (50 mg/m²), and paclitaxel (80 mg/m²) regimen for eight cycles
Trial: 24824852
Drug: Weekly dose-intensified
RxNorm normalized name: selinexor
DrugBank: Selinexor (DB11942)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Weekly dose-intensified cisplatin, epirubicin, and paclitaxel regimen
Trial: 24825411
Drug: Pitavastatin 4
RxNorm normalized name: PITAVASTATIN 4MG TAB
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pitavastatin 4 mg once daily (days 1-5 and 12-16)
Trial: 24825411
Drug: Darunavir 800
RxNorm normalized name: darunavir 800 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Darunavir 800 mg/ritonavir 100 mg once daily (days 6-16)
Trial: 24826798
Drug: sorafenib added
FDA approved: no
EMA approved: no
PMDA approved: no
Description: sorafenib added to endocrine therapy
Trial: 24827135
Drug: Panitumumab (9
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Panitumumab (9 mg/kg) combined with FEC100 (5-fluorouracil 500 mg/m², epidoxorubicin 100 mg/m², cyclophosphamide 500 mg/m²) followed by docetaxel (100 mg/m²), administered for eight cycles q.3 weeks and four cycles of FEC100 q.3 weeks, followed by four cycles of docetaxel q.3 weeks.
Trial: 24827135
Drug: Panitumumab in
RxNorm normalized name: panitumumab Injection
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Panitumumab in combination with FEC100 followed by docetaxel
Trial: 24829202
Drug: Oral 6-mercaptopurine
RxNorm normalized name: 6-Mercaptopurine
DrugBank: Mercaptopurine (DB01033)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Oral 6-mercaptopurine (6MP)
Trial: 24829343
Drug: RV144 HIV-1
RxNorm normalized name: Remune HIV-1
DrugBank: Remune (DB17772)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: RV144 HIV-1 vaccine
Trial: 24829492
Drug: 5-month fish-oil
RxNorm normalized name: Fish oil
DrugBank: Fish oil (DB13961)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 5-month fish-oil supplementation providing 1.4 g DHA/d plus 1.8 g EPA/d
Trial: 24829746
Drug: 10 μg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 10 μg CEA peptide (Arm A)
Trial: 24829746
Drug: 100 μg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 100 μg CEA peptide (Arm B)
Trial: 24829746
Drug: 1000 μg
RxNorm normalized name: menthol
DrugBank: Menthol (DB14123)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1000 μg CEA peptide (Arm C)
Trial: 24829756
Drug: pINGmuTyr vaccine
RxNorm normalized name: Pertussis vaccine
DrugBank: Pertussis vaccine (DB15274)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: pINGmuTyr vaccine at 1.5 mg dose
Trial: 24829756
Drug: pINGmuTyr vaccine
RxNorm normalized name: Pertussis vaccine
DrugBank: Pertussis vaccine (DB15274)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: pINGmuTyr vaccine at 0.2 mg and 0.5 mg doses
Trial: 24829756
Drug: pINGmuTyr vaccine
RxNorm normalized name: Pertussis vaccine
DrugBank: Pertussis vaccine (DB15274)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: pINGmuTyr vaccine
Trial: 24829756
Drug: pINGmuTyr vaccine
RxNorm normalized name: Pertussis vaccine
DrugBank: Pertussis vaccine (DB15274)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: pINGmuTyr vaccine followed by ipilimumab
Trial: 24829759
Drug: Recombinant Interleukin
RxNorm normalized name: Recombinant interleukin 2
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Recombinant Interleukin 21 (IL-21) plus sorafenib (400 mg twice daily)
Trial: 24830339
Drug: Fixed combination
RxNorm normalized name: Progestogens and estrogens, fixed combinations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fixed combination of inhaled beclometasone dipropionate and formoterol fumarate dry powder inhalers
Trial: 24830339
Drug: Free combination
RxNorm normalized name: SUNSCREEN-29 PABA-FREE COMBINATION LOT
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Free combination of inhaled beclometasone dipropionate and formoterol fumarate dry powder inhalers
Trial: 24831981
Drug: Lenalidomide (15
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Lenalidomide (15 mg oral on days 1-14) plus R-CHOP21 (375 mg/m² rituximab, 750 mg/m² cyclophosphamide, 50 mg/m² doxorubicin, 1.4 mg/m² vincristine on day 1, and 40 mg/m² prednisone on days 1-5)
Trial: 24834795
Drug: Denosumab (120
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Denosumab (120 mg) subcutaneously every four weeks, with additional doses on study days 8 and 15.
Trial: 24836963
Drug: Etravirine (ETV)
RxNorm normalized name: Etravirine
DrugBank: Etravirine (DB06414)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Etravirine (ETV) (once or twice daily)
Trial: 24839031
Drug: Golimumab 50
RxNorm normalized name: GOLIMUMAB 50MG/0.5ML INJ SYRINGE
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Golimumab 50 mg subcutaneous monthly for 6 months
Trial: 24843416
Drug: BIAsp70 (thrice-daily
FDA approved: no
EMA approved: no
PMDA approved: no
Description: BIAsp70 (thrice-daily injections)
Trial: 24843714
Drug: Sitagliptin 50
RxNorm normalized name: SITagliptin 50 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sitagliptin 50 mg/day
Trial: 24843520
Drug: Diet plus
RxNorm normalized name: Glucomannan/Grapefruit Extract/Pyridoxine Oral Tablet [GRAPEFRUIT DIET PLUS]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Diet plus low-dose pravastatin (10-20 mg/day, average 8.3 mg during follow-up)